Indeed, cysteine protease inhibitor K11777 has been tested in the murine model of schistosomiasis, and the remarkable reduction in worm burden and pathology validated schistosome cysteine proteases as novel potential drug targets for chemotherapy [10], [11]. Here, CTSB is linked to schistosomiasis.